Skip Page Header

Home > Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction, Europol. (2018) Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union. 10.2810/716236 I ISBN 978-92-9497-245-3.

[img]
Preview
PDF (Risk assessment ADB-CHMINACA)
1MB

This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. Synthetic cannabinoids such as ADB-CHMINACA are functionally similar to Δ9 -tetrahydrocannabinol (THC), the major psychoactive principle of cannabis. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.

Table of contents:
· Foreword
· EMCDDA actions on monitoring and responding to new drugs
Europol–EMCDDA Joint Report on ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) — a summary
· Risk Assessment Report on a new psychoactive substance: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
· Technical report on N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
· Participants of the risk assessment meeting, 7-8 November 2017


Item Type
Report
Publication Type
International, Report
Drug Type
Cannabis, New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Date
May 2018
Pages
83 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction, Europol
Place of Publication
Luxembourg
EndNote
Related (external) link

Repository Staff Only: item control page